You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Case Study: Efficacy of Orlistat 60 mg Treatment for Weight Loss

Smith, Tracey J. PhD, RD; Walker, Leila MS; Cummins, Deborah PhD; Crombie, Aaron PhD, RD; Funderburk, LesLee PhD, RD; Young, Andrew J. PhD; Touger-Decker, Riva PhD, RD

Topics in Clinical Nutrition:
doi: 10.1097/TIN.0b013e31826f8e02
Clinical Questions and Reviews
Abstract

Individuals who are overweight or obese are at risk for multiple comorbidities (eg, hypertension, dyslipidemia, type 2 diabetes, coronary artery disease). Pharmacotherapy combined with lifestyle modification, energy restriction, and increased physical activity has been suggested as a potential treatment option for overweight or obese individuals. Orlistat, one pharmacological treatment option, inhibits pancreatic and gastric lipase activity. It is available both as a prescription drug (120 mg taken 3 times per day with meals) and as an over-the-counter drug (60 mg taken 3 times per day with meals). The efficacy of orlistat 60 mg for weight loss in overweight and obese individuals is addressed in this article. A case study is also presented, which explores orlistat 60 mg use in a 31-year-old obese man, with emphasis on efficacy, compliance, and adverse effects.

Author Information

Department of Nutritional Sciences, School of Health Related Professions, University of Medicine and Dentistry of New Jersey, Newark (Drs Smith and Touger-Decker); US Army Research Institute of Environmental Medicine, Military Nutrition Division, Natick, Massachusetts (Drs Smith and Young, Ms Walker, MAJ Crombie, and LTC Funderburk); and the Academy of Nutrition and Dietetics, Chicago, Illinois (Dr Cummins).

Correspondence: Tracey J. Smith, PhD, RD, US Army Research Institute of Environmental Medicine, Military Nutrition Division, Kansas St, Bldg 42, Natick, MA 01760 (Tracey.J.Smith@us.army.mil).

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

© 2012 Lippincott Williams & Wilkins, Inc.